Trial · NCT04411472
Adverse events1,530
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 1,530
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Hypokalaemia | Metabolism and nutrition disorders | Placebo (Main Trial Safety Population, n=276) | 12 | 276 | 13 |
| other | Hypokalaemia | Metabolism and nutrition disorders | recAP 1.6 mg/kg (Main Trial Safety Population, n=280) | 15 | 280 | 15 |
| other | Hypokalaemia | Metabolism and nutrition disorders | Placebo (Moderate CKD Trial Safety Population, n=31) | 1 | 31 | 1 |
| other | Hypokalaemia | Metabolism and nutrition disorders | recAP 1.6 mg/kg (Moderate CKD Safety Population, n=30) | 0 | 30 | 0 |
| other | Hypokalaemia | Metabolism and nutrition disorders | Placebo (Covid-19 Safety Population, n=13) | 0 | 13 | 0 |
| other | Hypokalaemia | Metabolism and nutrition disorders | recAP 1.6 mg/kg (Covid-19 Safety Population, n=20) | 1 | 20 | 1 |
| other | Hypernatraemia | Metabolism and nutrition disorders | Placebo (Main Trial Safety Population, n=276) | 9 | 276 | 9 |
| other | Hypernatraemia | Metabolism and nutrition disorders | recAP 1.6 mg/kg (Main Trial Safety Population, n=280) | 11 | 280 | 11 |
| other | Hypernatraemia | Metabolism and nutrition disorders | Placebo (Moderate CKD Trial Safety Population, n=31) | 0 | 31 | 0 |
| other | Hypernatraemia | Metabolism and nutrition disorders | recAP 1.6 mg/kg (Moderate CKD Safety Population, n=30) | 0 | 30 | 0 |
| other | Hypernatraemia | Metabolism and nutrition disorders | Placebo (Covid-19 Safety Population, n=13) | 0 | 13 | 0 |
| other | Hypernatraemia | Metabolism and nutrition disorders | recAP 1.6 mg/kg (Covid-19 Safety Population, n=20) | 2 | 20 | 2 |
| other | Hyperkalaemia | Metabolism and nutrition disorders | Placebo (Main Trial Safety Population, n=276) | 3 | 276 | 4 |
| other | Hyperkalaemia | Metabolism and nutrition disorders | recAP 1.6 mg/kg (Main Trial Safety Population, n=280) | 8 | 280 | 8 |
| other | Hyperkalaemia | Metabolism and nutrition disorders | Placebo (Moderate CKD Trial Safety Population, n=31) | 0 | 31 | 0 |
| other | Hyperkalaemia | Metabolism and nutrition disorders | recAP 1.6 mg/kg (Moderate CKD Safety Population, n=30) | 0 | 30 | 0 |
| other | Hyperkalaemia | Metabolism and nutrition disorders | Placebo (Covid-19 Safety Population, n=13) | 1 | 13 | 1 |
| other | Hyperkalaemia | Metabolism and nutrition disorders | recAP 1.6 mg/kg (Covid-19 Safety Population, n=20) | 0 | 20 | 0 |
| other | Hypophosphataemia | Metabolism and nutrition disorders | Placebo (Main Trial Safety Population, n=276) | 5 | 276 | 5 |
| other | Hypophosphataemia | Metabolism and nutrition disorders | recAP 1.6 mg/kg (Main Trial Safety Population, n=280) | 7 | 280 | 7 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04411472/events